The relationship between the nitric oxide synthase gene and the risk of hypertension defi ned according to ambulatory blood pressures the impact of specifi c genetic loci on BP have employed 24-hour BP measurements in large study samples. Indeed, our group is one of the few that has recently employed this approach to assess 
INTRODUCTION
A high proportion of the risk for cardiovascular events is attributed to hypertension. (1) Despite the risk associated with hypertension, apart from age and body size, the factors that account for most of the variation in blood pressure (BP) at a population level have remained elusive. Nevertheless, familial aggregation and heritability analyses indicate that a signifi cant proportion of BP variability can be attributed to genetic effects. (2) (3) (4) However, in this regard, there has been an inability to replicate genetic outcomes of even large studies evaluating genome-wide associations. (5, 6) The reasons for inconsistencies in the scientifi c literature with regards to the role of genetic loci in contributing to variations in BP are potentially numerous. However, one confounding factor that has been overlooked is that in the absence of repeated BP measurements obtained over considerable time periods, (6) 24-hour ambulatory as opposed to offi ce BP measurements may be required to increase the ability to show familial aggregation or the heritability of BP. (2) (3) (4) Nevertheless few studies assessing the role of genes that infl uence the renin-angiotensin-aldosterone system in hypertension. (7, 8) In addition, a study to determine the impact of leptin gene variants on blood pressure used ambulatory monitoring to assess blood pressure. (9) To extend these studies, in the present study we assessed the ability to detect a relationship between a common variant of the endothelial nitric oxide synthase (eNOS) gene and the presence of hypertension confi rmed with 24-hour BP measurements in a large case-control study. In this regard, in studies employing conventional BP measurements to identify the presence of hypertension or the variability of BP, the role of the eNOS gene in contributing to hypertension or BP variability has produced inconsistent outcomes.
(10-21) 
METHODS

Study groups
Ambulatory blood pressures and grading of hypertension
Ambulatory BP measurements were performed at least every half hour during the day (06:00 to 22:00 hours) and hourly during the night (22:00 to 06:00). Ambulatory monitors were calibrated using standard techniques. All patients were advised not to smoke, drink alcohol, or ingest caffeine during this period.
Five hundred and three patients had >90% and the remaining >85% of intended ambulatory BP recordings obtained. The grading of hypertension was based on the mean values obtained for daytime ambulatory BP and the categories (I, II and II) were according to those described in guidelines for the diagnosis and management of hypertension.
(1)
Genotyping
Deoxyribonucleic acid was extracted from whole blood by lysing red blood cells and digesting the remaining white cell pellet with proteinase K. A functional variant (22) in exon 7 of the eNOS gene was studied, where a substitution of a thymidine for a guanine nucleotide at position 894 results in aspartate (Asp) replacing glutamate (Glu) in amino acid position 298 of the protein. 
Data analysis
To test for Hardy Weinberg equilibrium, the expected genotype numbers were calculated from the allele frequencies and deviation from the observed genotype numbers was determined using a 
RESULTS
Demographic and clinical characteristics
Demographic and clinical data for the study groups are shown in Table 1 . Both the case and the control groups had more females than males and a mean body mass index that refl ects a high prevalence of obesity. The high proportion of females in both groups refl ects the gender distribution of patients attending district clinics rather than a greater incidence of hypertension in women as compared to men. Except for a higher BMI in the case group, the case and control groups were matched for all other demographic features. However, the eNOS Glu/Glu genotype group in the hypertensives consisted of more females (p<0.05) and had a trend for a higher mean BMI (p<0.05) than the patients with the Glu/Asp and Asp/Asp genotypes.
Genotype effects on the risk of hypertension
The genotype frequencies of the eNOS gene variant in the case and the control groups are given in Table 2 . The genotype frequencies were in Hardy Weinberg equilibrium for both the case and the control groups. The eNOS gene variant was however not independently associated with the presence of hypertension (Table 2) .
Genotype effects on ambulatory blood pressure Genotype effects on the severity of daytime ambulatory blood pressure 
NO SYNTHASE GENE AND AMBULATORY BP
DISCUSSION
The main fi ndings of the present study are that in a large study sample (n=1014), in which hypertension in the case group was confi rmed with ambulatory BP monitoring, the Glu298Asp polymorphism of the eNOS gene is not associated with the presence of hypertension. However, within the hypertensive group, patients with the Glu/Glu genotype had a ~3-7 mm Hg greater ambulatory BP than patients with other eNOS genotypes, and the eNOS genotype was associated with the severity of hypertension and contributed ~1.4-2.5% to the variation in ambulatory blood pressure within hypertensive patients.
The present study is the fi rst to evaluate the relationship between the well described functional (21) Glu298Asp variant of the eNOS gene and the presence of hypertension in patients in whom the diagnosis was confi rmed with ambulatory BP monitoring whilst off medication. Previous studies have evaluated the relationships between eNOS gene variants and the presence genotypes and the presence of hypertension, (12, 13, 15) another a relationship between the Glu/Glu genotype and hypertension, (10) whilst in further studies a lack of relationship between the Glu298Asp genotype and the presence of hypertension was noted. (18) (19) (20) (21) In this regard, the strongest evidence, obtained in large study samples (n=1165-4055), (18, 20) indicates that the Glu298Asp variant is indeed not associated with hypertension.
Moreover, our study, also conducted in a large study sample (n=1014) and with the additional benefi t of the presence of diastolic hypertension confi rmed off medication using ambulatory BP monitoring, concurs with the outcomes of previous studies conducted in large study samples (18, 20) indicating that the Glu298
Asp variant is indeed not associated with hypertension.
Although in the present study we were unable to show a relationship between Glu298Asp genotype and the presence of hypertension, we were able to show a fairly robust relationship between this genotype and ambulatory BP in hypertensives not receiving medication at the time of assessment. These data would suggest that the eNOS gene may be associated with BP, but that the sensitivity to detect an effect is enhanced by considering BP as a continuous rather than a dichotomous trait and employing ambulatory BP to assess these effects. This is indeed consistent with the notion that ambulatory BP measurements enhance the ability to detect a genetic effect as previously proposed. (2) (3) (4) It may be argued that the genetic association described in the present study with ambulatory BP in hypertensives is of little clinical relevance if ambulatory BP is required to detect a difference in BP between genotype groups. Importantly, however, the differences in ambulatory BP detected in patients with the Glu/Glu as compared to those with the Glu/Asp and Asp/Asp genotypes were of clinical signifi cance in that they translated into an association with different grades of severity of hypertension defi ned according to mean daytime BP measurements. In this regard, grade II and III hypertension carries a signifi cantly greater risk of a cardiovascular event than grade I hypertension.
An explanation for the relationship between the Glu/Glu genotype of the Glu298Asp variant and an increased ambulatory BP was not explored in the present study. In this regard, the Asp298 allele is associated with the production of an eNOS protein that is more susceptible to cleavage than the 298Glu allele (22) an effect that is likely to reduce NO production and consequently increase and not decrease BP as reported on by our group. Hence, in the present study two explanations for the relationships between genotype and ambulatory BP need to be considered. First, the Glu298Asp variant may be in linkage disequilibrium with an alternative functional eNOS gene variant. Second, the association noted may be explained by an increased mortality in hypertensive participants with the Asp298 allele with more severe forms of hypertension. In the latter case the remaining patients with the Asp298 allele would have lower BP values as reported on by us.
Only prospective studies will be able to evaluate this hypothesis.
The strengths of the present study include the relatively large study sample evaluated (n=1014) and the use of ambulatory BP in 503 hypertensives to assess the outcomes. The limitations of the present study include the lack of prospective analysis. Thus the outcomes of the present study may represent an epiphenomenon. Moreover, the relationship between genotype and ambulatory BP was assessed in hypertensives rather than in a crosssection of the population. In this regard, further work is being conducted to assess the relationship between eNOS genotype and ambulatory BP in ~750-1000 participants derived from a cross-section of the population.
In conclusion, in the present study conducted in a large cohort (n=1014) in which hypertension in the cases was confi rmed using 24-hour ambulatory BP monitoring, we show that the functional Glu298Asp gene variant of the eNOS gene is not associated with hypertension. However, within the hypertensive group, a robust relationship between eNOS genotype and variations in ambulatory BP was observed. The latter important relationship observed in the hypertensives requires further investigation.
